
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1092 | 1062 | 1100 | 1240 | 1539 | 1508 |
Fund Return | 9.16% | 6.25% | 9.96% | 7.42% | 9% | 4.19% |
Place in category | 117 | 130 | 260 | 152 | 165 | 153 |
% in Category | 25 | 32 | 70 | 41 | 49 | 72 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Beacon Small Cp Val Inst | 1.63B | -2.35 | 4.76 | 7.27 | ||
US0245267903 | 1.43B | 4.56 | 9.91 | - | ||
American Beacon Lg Cap Value Inst | 1.06B | 4.56 | 9.88 | 9.33 | ||
American Beacon The London Co Inc Y | 650.83M | 6.33 | 6.05 | 8.54 | ||
American Beacon Lg Cap Value Inv | 475.41M | 4.53 | 9.55 | 8.97 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Dodge & Cox International Stock | 40.34B | 9.46 | 7.83 | 4.82 | ||
Fidelity Series International VVV | 15.18B | 10.65 | 10.77 | 6.14 | ||
Causeway International Value Instl | 13.16B | 11.37 | 12.02 | 6.12 | ||
Vanguard International Value Inv | 12.28B | 6.12 | 4.57 | 4.68 | ||
DFA International Value I | 9.89B | 9.23 | 9.37 | 5.88 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Msci Eafe Mar25 Ifus 20250321 | - | 3.65 | - | - | |
Roche Holding Participation | CH0012032048 | 2.80 | 309.20 | +1.01% | |
Reckitt Benckiser | GB00B24CGK77 | 2.37 | 5,194.0 | -0.12% | |
Sanofi | FR0000120578 | 2.09 | 105.84 | -0.34% | |
GSK plc | GB00BN7SWP63 | 2.08 | 1,509.00 | -0.13% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Sell |
Technical Indicators | Strong Buy | BUY | Strong Sell |
Summary | Neutral | Neutral | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review